InvestorsHub Logo

nofanofthis

11/30/13 2:56 PM

#22296 RE: gta888 #22295

I think we are in the 90% group until we get a management change. We need fresh blood to reestablish relationships with Big Pharm. We will never get a $20 offer again but perhaps a $4 or $5. This management team is not only shunned by the FDA but also by Big Pharm. I believe this is our only hope.... Otherwise watch for a long two years ending with a dilution or delisting.

sts66

12/01/13 12:02 PM

#22310 RE: gta888 #22295

Oh, AMRN is definitely NOT in that 90% group - that's the number of small bios that fail to produce a commercial drug and fold, IIRC. We're way past that point - now it's sales and marketing, plus expanding indication and R-IT results. AMRN will survive somehow, as opposed to a company like VVUS, which is likely to fold under a mountain of debt and the REMS CVOT trial costs within 12-18 months - they will have a HUGE problem raising new funds - already have the same kind of loan shark deal with Pharmakon that AMRN has, and only an idiot would buy shares in an offering - and they're bleeding $50M+ per quarter. Dead man walking. We're not.